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creativecommons.org/licenses/by-nc-nd/4.0/).miRNA-guided diagnostics is a powerful molecular approach for
evaluating clinical samples through miRNA detection and/or
visualization. To date, this approach has been successfully used to
diagnose, manage, and/or monitor a wide range of neoplastic and
non-neoplastic diseases. Despite the promise of miRNA-guided
diagnostics, particularly in the ﬁeld of minimally invasive bio-
markers, several knowledge and practical issues confound or
hinder translation into routine clinical practice including: miRNA
sequence database errors, suboptimal RNA extraction methods,
detection assay variability, a vast array of online resources for
bioinformatic analyses, and non-standardized statistical analyses
for miRNA clinical testing. In this review, we raise awareness of
these issues and recommend research directions to help specialists
in endocrinology and metabolism integrate miRNA testing into
clinical decision-making.
© 2016 The Authors. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
microRNA (miRNA)-guided diagnostics is a powerful molecular approach for deriving clinically
signiﬁcant information from patient samples. miRNAs are small (19e24 nt) endogenous RNA. Gustafson), kt40@queensu.ca (K. Tyryshkin), neil.renwick@queensu.ca
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able biomarkers due to their cell-type speciﬁcity, abundance, and stability [1e4]. The clinical utility of
miRNA-guided diagnostics builds on more than a decade of research showing that miRNAs regulate
numerous developmental and physiological processes and that miRNA dysregulation is a common
mechanism of disease [5,6]. Using neoplastic diseases as an example, miRNA-guided diagnostics has
been successfully used to classify cancer [7], identify cancer tissue origin [8], determine prognosis and
disease progression [9], predict chemoresistance [10], monitor therapy [11], and screen for disease
[12]. The detection of miRNAs in most solid [2] and liquid [13] clinical samples highlights their
promise as disease biomarkers.
Despite the potential for miRNA-guided diagnostics in the diagnosis and management of endo-
crine cancers and metabolic disorders, some mindfulness should be practiced when working with
these small RNA molecules. Even when using typical diagnostic workﬂows and familiar miRNA
detection technologies, several knowledge or methodological issues may confound or hinder miRNA
diagnostic testing, including: differing usage of miRNA nomenclature [14], annotation assignment
errors [15], suboptimal RNA extraction [16], detection assay variability [17e19], a bewildering array of
online bioinformatics resources [20], and non-standardized statistical analyses for miRNA clinical
testing [21]. Although these issues will resolve over time, awareness will facilitate standardization of
miRNA diagnostic testing and enable inter-laboratory comparisons.
Here, we provide an overview of miRNA-guided diagnostics for specialists in endocrinology and
metabolism (Fig. 1). Following a brief refresher onmiRNA biogenesis, we discuss miRNA discovery and
sequence characteristics, nomenclature, database curation, expression in human tissues, pre-
analytical variables in miRNA testing, detection methods, online bioinformatic resources, and sta-
tistical analyses, emphasizing certain issues that, in our opinion, impede meaningful miRNA diag-
nostic testing. Nonetheless, as this increasingly powerful molecular approach matures, we expect
miRNA-guided diagnostics to greatly assist clinical decision-making through quantitative detection
of novel tissue-based and/or minimally invasive biomarkers.
miRNA biogenesis
To appreciate the intricacies of miRNA-guided diagnostics, a brief refresher on miRNA biogenesis is
provided below. miRNAs negatively regulate gene expression by binding to complementary regions inFig. 1. Typical miRNA diagnostic workﬂow. Typically, miRNAs are extracted from solid and liquid clinical specimens using guanidium
thiocyanate-phenol-chloroform, commercial ﬁlter-based spin baskets, magnetic particles, or direct lysis methods; this step is
bypassed for miRNA visualization in tissue sections using miRNA in situ hybridization. RNA quality control is subsequently per-
formed using UV spectrophotometry and agarose/polyacrylamide gel electrophoresis or ﬂuorescent dye-based quantitation to assess
RNA yield, purity, and integrity. Next, miRNAs are detected in clinical samples using sequencing-based, ampliﬁcation-based, or
hybridization-based methods followed by method-speciﬁc data acquisition and statistical analysis.
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of the RNA-induced silencing complex (RISC) which, in turn, inhibits protein synthesis through
translational repression, mRNA deadenylation and decay, or transcript cleavage [22,23]. miRNAs are
encoded within the human genome and are generated from long primary transcripts through ca-
nonical or non-canonical processing pathways (Fig. 2). Canonical processing involves enzymatic
cleavage of an ~21 bp miRNA/miRNA* duplex molecule from an ~60e100 nt precursor stem-loop
structure in the primary transcript by Drosha and Dicer; these enzymes are located in the nucleus
and cytoplasm, respectively. Following duplex unwinding, one strand (termed the mature miRNA) is
loaded onto AGO protein whereas the other (miRNA*) strand is rapidly degraded. Sometimes both
miRNA and miRNA* strands are produced in similar amounts and these strands are given -5p and -3p
sufﬁxes to denote their positions in the miRNA precursor molecule and to indicate their targeting
ability. It is important to note that miRBase (see Section miRNA online resources) now uses -5p andFig. 2. Overview of miRNA biogenesis. (A) Canonical pathway. Long primary transcripts (pri-miRNA) are generated through RNA
polymerase II (Pol II)-mediated transcription. Stem-loop structures in the pri-miRNA are enzymatically cleaved by Drosha and its co-
factor DGCR8 in the nucleus (continued below). (B) Non-canonical pathway. Mirtrons, as an example, are enzymatically fashioned
from spliced introns by debranching RNA lariats 1 (DBR1). In both pathways, precursor miRNA molecules (pre-miRNAs) are exported
to the cytoplasm by the nuclear export factor exportin-5. miRNA duplex molecules are subsequently cleaved from the stem-loop
structure by Dicer and its co-factor TRBP. Following duplex unwinding, the mature miRNA strand is incorporated into Argonaute
(AGO)1e4 whereas the miRNA* strand is rapidly degraded. AGO facilitates processing of pre-miRNA and association of the RNA-
induced silencing complex (RISC) which when assembled inhibits protein synthesis through translational repression, mRNA
deadenylation and decay, or transcript cleavage.
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canonical processing involves bypassing either the enzymatic cleavage step or leveraging spliceoso-
mal activity to generatemiRNAs from introns (termedmirtrons); non-canonical processing in humans
is comparatively rare. Following processing and loading onto AGO protein, the seed sequence (po-
sitions 2e8 of the mature miRNA molecule) serves as a landing strip for complementary sequences in
the 30-untranslated regions of target mRNAs.
miRNA biogenesis is challenging to study biochemically. However, this process can be readily
monitored through next-generation sequencing and subsequent alignment of miRNA/miRNA* or
-5p/-3p sequences against a reference human genome; this approach is also useful for miRNA dis-
covery, curation, and expression proﬁling (see sections miRNA discovery and sequence
characteristicsemiRNA database curation). Canonical and some non-canonical (e.g. mirtron) path-
ways yield similar processing patterns with two sequence peaks, corresponding to miRNA/miRNA* or
-5p/-3p sequence pile-ups, separated by a space corresponding to the loop region that is excised by
Drosha; for other non-canonical products, only one sequence pile-up may be seen. Because enzymatic
processing of RNA substrates can vary, each sequence pile-up contains a population of sequences that
can shift register by a few nucleotides in either direction; the most abundant sequences are used to
deﬁne miRNA/miRNA* and -5p/-3p products. Sometimes, sequences near the 50- and 30-ends of the
miRNA precursor molecule can be seen in sequencing but these miRNA-offset RNAs likely represent
processing byproducts rather than functional molecules [24].
miRNA discovery and sequence characteristics
miRNA discovery is the ﬁrst step inmiRNA-guided diagnostics and typically results from small RNA
sequencing studies of clinical specimens. Subsequently, candidate miRNA sequences are aligned
against a reference human genome and accepted or rejected using non-standardized sequence-based
criteria; this process has led to some annotation assignment errors in online miRNA sequence re-
positories, such as miRBase. Several groups have proposed criteria for identifying miRNAs in sequence
data including the presence of: (i) miRNA/miRNA* or -5p/-3p sequence reads that are mostly com-
plementary with a 2 nt 30 overhang, (ii) a predilection for U or A nucleobases at the miRNA 50-end, and
(iii) comparatively less processing variation at the miRNA 50-end than at the 30-end [25e27]. More
recently, the curators of miRBase have deﬁned a set of high conﬁdence miRNAs based on (i) perfect
mapping of at least ten sequence reads to the -5p/-3p products derived from the miRNA precursor
molecule, and (ii) pairing of these -5p/-3p products into a miRNA duplex with 0e4 nt 30 overhang,
among other criteria [14]. Through these approaches, an unambiguous set of miRNA sequences will be
deﬁned for accurate miRNA-guided diagnostics.
miRNA nomenclature
Knowledge of miRNA nomenclature is beneﬁcial for ordering and interpreting miRNA diagnostic
tests. miRNAs are named using a conventional preﬁx-name-number-sufﬁx format (e.g. hsa-miR-1-1
or hsa-miR-133a). The preﬁx hsa- (Homo sapiens) is used for all human miRNAs. The names “miR”
or “mir” refer to the mature miRNA and precursor miRNA gene or stem-loop structure, respectively.
Numbers (i.e. numerical identiﬁers) are assigned sequentially to miRNAs in order of discovery. The
sufﬁxes -1, -2 and -a, -b respectively indicate occasions when identical or near-identical mature
miRNA sequences are generated from two distinct precursor loci. Two emerging preﬁxes are also of
interest; sequence families (sf-) are groups of miRNAs that share the same seed sequence for mRNA
targeting and genomic clusters (cluster-) indicate groups of miRNAs that are co-transcribed.
Knowledge of sequence families and genomic clustering is helpful for evaluating miRNA targeting
and function.
miRNA database curation
miRNA database curation is essential for sorting miRNAs from miRNA mimic sequences (e.g.
turnover products of more abundant non-coding RNAs). Inadequate miRNA curation directly impacts
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affects all analyses. Currently, 2588 mature human miRNAs are listed in miRBase version 21, although
this may be an underestimate given that some entries are missing -5p and -3p designations. To
facilitate more reliable miRNA-guided diagnostics, some groups are curating human miRNAs using
knowledge of canonical and non-canonical processing and ever increasing amounts of small RNA
sequencing data from different human tissues and cell lines [27,28].
To date, the most comprehensive curation attempt incorporates sequencing-based miRNA
expression proﬁles from more than 2000 clinical specimens [27,29]. miRNA sequences were down-
loaded from miRBase and mapped against the human genome with subsequent mapping of pooled
sequences against an extended precursor molecule sequence to assess miRNA biogenesis patterns.
Canonical miRNAs were accepted as “correct” based on (i) sufﬁcient sequence read evidence, (ii)
sequence mapping to a limited number of genomic regions and absence of mapping to other non-
coding RNA loci, (iii) evidence of two sequence peaks separated by a space, (iv) predicted folding of
dominant sequence reads into a stem-loop structure, (v) predilection for U or A nucleobases at the
miRNA 50-end, (vi) comparatively less processing variation at the miRNA 50-end, (vii) evidence of
evolutionary conservation, and (viii) supportive expression evidence such as genomic clustering or
expressed sequence tags. With this approach, 1112 canonical mature and miRNA* sequences were
identiﬁed; 426 miRNAs were organized into sequence families and 237 of 557 precursors were
organized into genomic clusters [27]. Through iterative miRNA database curation efforts, incorpo-
rating new sequence data and information on non-canonical miRNAs, a deﬁnitive set of miRNA se-
quences will be established for accurate miRNA-guided diagnostics.
miRNA expression in human tissues
In 2007, the enormous potential for miRNA-guided diagnostics became clearer with the publica-
tion of the ﬁrst comprehensive mammalian miRNA atlas [1]. In this landmark study, 256 small RNA
libraries from 26 different human and rodent organ systems and cell types were generated through
cloning and sequencing, providing a wealth of information on miRNA sequences, genomic organi-
zation, and expression. Expression proﬁling showed that some miRNAs, such as miR-21, are ubiqui-
tously expressed whereas others are speciﬁcally expressed (Table 1). The latter group is extremely
helpful for interpreting and for controlling the quality of miRNA clinical data; for instance, if miR-122
is detected in a non-hepatic sample, this more likely represents a sample mix-up or contamination
rather than an interesting genetic phenomenon. Recently, a different research group released an
updated version of this atlas (https://ccb-web.cs.uni-saarland.de/tissueatlas) using microarray ana-
lyses to examine the expression of 1997miRNAs in 61 post-mortem tissue biopsies [30]. Interestingly,
only 143 (10.5%) of 1364 detected miRNAs were present in all samples while the remainder showed
differing degrees of tissue speciﬁcity d a key point supporting the utility of miRNA-guided di-
agnostics. In addition, a staggering 633 (31.7%) of 1997 miRNAs were not detected in this study,Table 1
Commonly encountered tissue-speciﬁc miRNAs that aid interpretation and quality control of miRNA
clinical data.
Organ system miRNA
Cardiovascular system miR-150
Connective tissue miR-483
Embryo miR-153, miR-302a, miR-488
Endocrine gland miR-9, miR-7, miR-137, miR-375
Hematopoietic system miR-142, miR-150, miR-223
Kidney miR-146a
Liver miR-122
Musculoskeletal system miR-1, miR-133, miR-206, miR-208, miR-499
Nervous system miR-9, miR-124
Reproductive system miR-371, miR-888
Respiratory system miR-224
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miRNA proﬁling studies of non-diseased tissues and cell lines will certainly help establish the full
spectrum of miRNAs encoded in the human genome and clarify whether there are any expression
differences between ethnic groups [31].
Pre-analytical variables in miRNA testing
Pre-analytical variables are potential sources of inconsistency in miRNA testing, resulting from
differences in sample collection, handling and processing, nucleic acid extraction and quality control,
and physiological variations between individuals [32]. These pre-analytical variables can be considered
as common to all samples or speciﬁc to solid or liquid clinical specimens [32]. Common variables
include differences in RNA extraction and quality control, miRNA stability, individual variance (e.g. age
and race), and concurrent drug or medication use or chemical exposure. Tissue-speciﬁc variables
include: specimen time ex vivo, type of ﬁxative, and storage conditions and inherent stability. Liquid
sample-speciﬁc variables include: specimen collection (use of additives such as heparin), storage and
stability, blood cell count, hemolysis, plasma volume, and plasma components. As exempliﬁed by
Ludwig et al. [30], explicit recording of pre-analytical variables facilitates inter-study comparisons and
identiﬁcation of best practices for optimal miRNA testing. Below, we focus on three readily addressable
pre-analytical variables, namely RNA extraction, quality control, and stability, which should reduce
some of the current variability in miRNA-guided diagnostics.
Optimized RNA extraction methods are required to derive maximal miRNA information content
from clinical samples. Currently, miRNAs can be extracted from a wide range of fresh and archived,
solid and liquid clinical specimens using organic extraction (e.g. guanidium thiocyanate-phenol-
chloroform), ﬁlter-based spin basket formats, magnetic particle methods, or direct lysis methods
[33]. Attempts have been made to optimize miRNA extraction [34] because many investigators have
compared miRNA extraction methods [35,36] and noted that miRNA recovery is inﬂuenced by isolation
method and the amount of RNA input [37]. One recent approach for isolating miRNAs from liquid
samples involves the use of radiolabeled spike-in markers, inactivation of nucleases, removal of protein
through protease digestion, and collection of RNA in small volumes that are free of denaturants to avoid
impairing subsequent enzymatic reactions (Thomas Tuschl, personal communication). This innovative
approach allows better monitoring of miRNA input and output through the extraction procedure and
avoids using miRNA detection/readout systems that are also subject to variation.
RNA quality control is essential for understanding the amount, purity, and integrity of RNA that can
be used in miRNA clinical testing. Typically, RNA quality is assessed through a combination of UV
spectrophotometry and agarose/polyacrylamide gel electrophoresis or ﬂuorescent dye-based quan-
titation. Each approach has respective shortcomings that can impact miRNA testing, including: (i)
generation of misleading absorbance readings due to the presence of DNA or extraction reagents, and
(ii) photo-degradation, binding of the ﬂuorescent dye to the side of the tube or to DNA in solution, or
damage to the RNA standards through repeated freeze-thawing cycles. Although currently not for
diagnostic use, commercial systems, such as the Agilent Bioanalyzer instruments, NanoDrop™
spectrophotometers and ﬂuorospectrometers, and Qubit® ﬂuorometers, provide excellent RNA
quality control, reducing under- or over-estimation of RNA input into detection assays and enabling
inter-study comparisons.
miRNA stability in solid and liquid clinical samples should be fully investigated to unlock their
potential as highly informative tissue biomarkers and minimally invasive biomarkers. miRNAs are
present in a wide range of fresh tissues and cells [1,30] and their expression is stable following
artiﬁcial degradation (incubation at 80 C for 240 min) or prolonged storage in physiological salt
solution (incubation at 4 C for 14 d) despite dramatic decreases in RNA integrity [2,30]. miRNAs are
also detectable in formalin-ﬁxed parafﬁn-embedded (FFPE) tissues blocks [38], even after a decade of
storage [35,39], with excellent correlation between miRNA proﬁles generated from fresh and FFPE
tissues [40]. Remarkably, miRNAs are stable in plasma [3] and serum [4]. In plasma, miRNAs are
resistant to endogenous RNase activity and detectable following extended storage or multiple freeze-
thawing cycles [3]. In serum, miRNAs are similarly resistant to RNase digestion, boiling, low/high pH,
extended storage, andmultiple freeze-thawing cycles [4]. In plasma, resistance to degradation is more
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[41,42]. Although, it is currently unclear whether plasma or serum is the better source for analyzing
circulating miRNAs [43], there is strong evidence that plasma miRNAs can be used as minimally
invasive biomarkers [44].
miRNA detection methods
Accurate miRNA detection and/or visualization in clinical samples are core activities in miRNA-
guided diagnostics. To enable these activities, sequencing-based, ampliﬁcation-based, and
hybridization-based approaches have been designed, leveraging or working around the small size,
sequence heterogeneity, and 50-P and 30-OH termini of miRNA molecules. Common approaches to
miRNA clinical testing include small RNA sequencing [29,45], quantitative miRNA real-time reverse-
transcription PCR (qRT-PCR) [46], miRNA microarray [47], multiplexed miRNA detection with color-
coded probe pairs [48], and miRNA in situ hybridization [49]. Below, we brieﬂy describe these com-
mon approaches to facilitate matching of an appropriate detection method to a corresponding
diagnostic need, keeping in mind that clinical testing should be rapid, sensitive, accurate, labor non-
intensive, easy to analyze, and cost-effective (see Table 2). It should be noted that cross-platform
comparisons of miRNA detection are gradually improving over time [18,50]; emerging miRNA
detection technologies are expertly reviewed elsewhere [51,52].Small RNA sequencing
miRNA sequencing is rapidly becoming the method of choice for comprehensive miRNA proﬁling in
clinical samples. This approach involves adapter ligation to miRNA 50- and 30- ends, reverseTable 2
Comparison of miRNA detection methods commonly used in clinical practice.
Method Advantages Disadvantages RNA input
Small RNA sequencing
Sequencing-based detection Comprehensive proﬁling
Multiplexed
Quantitative
High sensitivity
High speciﬁcity
Highly labor intensive
30 adapter ligation bias
Requires bioinformatics analysis
Comparatively expensive
ng-mg
Quantitative miRNA real-time reverse-transcription PCR
Ampliﬁcation-based detection Clinically tractable
Limited proﬁling
Multiplexed
Quantitative
High sensitivity
High speciﬁcity
Comparatively inexpensive
Moderately labor intensive
Sensitive to contaminants
<ng
miRNA microarray
Hybridization-based detection Clinically tractable
Comprehensive proﬁling
Multiplexed
Relative quantitation
Low sensitivity
Low speciﬁcity
Comparatively expensive
ng-mg
NanoString nCounter expression system
Hybridization-based detection Limited proﬁling
Multiplexed
Quantitative
High sensitivity
High speciﬁcity
Comparatively expensive
Emerging methodology
ng
miRNA in situ hybridization
Hybridization-based detection Preserves tissue architecture
Multiplexed
Quantitative
Labor intensive
Comparatively expensive
Emerging methodology
N/A
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purpose-built annotation pipelines (see Section miRNA online resources); higher sample throughput
can be obtained using barcoded 30 adapters [29] or PCR barcoding [45]. Sequencing provides
comprehensive quantitative miRNA expression data, can be highly multiplexed, and has high sensi-
tivity and speciﬁcity [53]. However, this method is labor intensive, subject to 30 adapter ligation biases
[54], requires specialized bioinformatic analyses [55], and is expensive. Adapter ligation and PCR
ampliﬁcation steps can be avoided using single molecule technologies, such as Helicos single-molecule
sequencing and nanopore-based approaches [56,57].
Quantitative miRNA real-time reverse-transcription polymerase chain reaction
miRNA qRT-PCR is a widely used method in clinical testing, however, it seems best suited to
detecting, quantitating, and/or validating single or limited subsets of miRNAs. This approach involves
reverse transcription, PCR ampliﬁcation, and ﬂuorescent detection of PCR products. Because miRNAs
are only 19e24 nt in length, poly(A) tailing of miRNA 30-ends or use of miRNA-speciﬁc stem-loop
primers enable subsequent reverse transcription [46,58]. During ampliﬁcation, PCR products can be
monitored through incorporation of a ﬂuorescent dye, such as SYBR Green Dye, into double-stranded
DNA or release of a ﬂuorophore from a degraded Taqman® probe [46,58]. miRNA qRT-PCR is clinically
tractable, multiplexed, quantitative, has high sensitivity and speciﬁcity, and is comparatively inex-
pensive. However, the method is moderately labor intensive and sensitive to contaminants such as
nucleases or PCR inhibitors; there is considerable discussion over using synthetic RNA spike-in cal-
ibrators and U6 snRNA as exogenous and endogenous gauges of miRNA extraction and ampliﬁcation.
miRNA microarray
miRNA microarrays are also used for comprehensive miRNA proﬁling in clinical samples. This
approach involves ﬂuorescent labeling of miRNAmolecules, hybridization of labeled miRNAmolecules
to complementary probes immobilized on glass slides, and detection and quantitation of ﬂuorescence
emission at known probe location [59]. miRNA microarray is clinically tractable, comprehensive, and
multiplexed [60]. However, it is labor intensive, provides relative quantitation only, has low sensitivity
and speciﬁcity, and can be expensive if locked nucleic acids are used in probe design. A similar solution-
phase hybridization methodology is also available, detecting miRNAs in clinical samples using capture
probes linked to ﬂuorescence-labeled microbeads to detect miRNAs in clinical samples [7].
Nanostring nCounter gene expression system
Highly multiplexed miRNA detection in clinical samples through the use of two target speciﬁc
probes for each miRNA is an emerging and innovative technology [48]. This approach involves
capturing target miRNAs in solution using a biotin-labeled 30 capture probe and a second 50 reporter
probe with an individual color-coded sequence. Following puriﬁcation, a tripartite molecule is bound
and immobilized on a streptavidin-coated slide with subsequent imaging and counting of the
immobilized reporters. This approach is clinically tractable, moderately comprehensive, quantitative,
has high sensitivity and speciﬁcity, and avoids bias prone ampliﬁcation and ligation steps. However, it
is comparatively expensive and is currently an unfamiliar system for miRNA detection.
miRNA in situ hybridization
Chromogenic or ﬂuorescence in situ hybridization (CISH or FISH) approaches to visualize miRNAs
in fresh frozen or FFPE tissue sections have been developed by several groups [49,61e67]. This
approach involves detecting miRNAs in tissue sections using labeled complementary nucleic acid
probes. Typically, this approach includes probe design, ﬁxation, permeabilization, hybridization, post-
hybridization washing, signal ampliﬁcation, and signal detection steps. Recently, a multiplexed
miRNA FISHmethod was designed for endocrine tumor differential diagnosis [61,68], using (i) EDC (1-
ethyl-3-(3-dimethylaminopropyl) carbodiimide) to crosslink miRNAs to surrounding proteins
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avoid mishybridization to more abundant RNAs such as ribosomal RNA, and (iii) long linkers between
the probe and the hapten to improve signal detection and ampliﬁcation. The major advantages of ISH
are preservation of tissue architecture, multiplexing capacity, and the ability to quantitate if a reliable
reference probe is used. However, this method is labor intensive, comparatively expensive, and an
unfamiliar system for miRNA detection.
miRNA online resources
miRNA-guided diagnostics relies heavily on computational tools and online resources [20]. These
resources have been categorized into (i) databases and repositories of miRNA sequences and
expression, (ii) miRNA target prediction algorithms, (iii) tools for miRNA functional investigation, and
(iv) online pipelines for analysis of high throughput experiments [20]. Useful resources include: (i)
miRBase e a frequently updated miRNA sequence and expression database containing genomic lo-
cations, precursor and mature miRNA sequences, and helpful links [14], (ii) TargetScan [69] and
DIANA-TarBase [70] websites respectively providing predicted and experimentally validated miRNA
targets for pathomechanistic insights, (iii) DIANA miRPath v.2.0 [71] and miR2Disease [72] websites
respectively integrating miRNA activity into pathways analyses or linking miRNAs to phenotypes or
diseases, and (iv) miRAnalyzer [73] for analyzing small RNA sequencing data. This important topic has
been expertly reviewed elsewhere [20].
miRNA statistical analyses
Prior to any statistical analysis, miRNA data or test results, regardless of data type or origin, should
be visualized to gain an understanding of the data set and to uncover batch effects or poor quality
samples. Samples should be graphed on the x-axis in order of collection or processing. Descriptive
statistics, such as median expression, inter-quartile range (showing data variability), mean Spearman
correlation to all other samples (showing sample similarity), or box plots (showing the distribution
and range of miRNA data in each sample), should be presented on the y-axis. Sample outliers can be
identiﬁed using the inter-quartile range (IQR) method [74,75]. Data should subsequently be pre-
processed, removing technical variation through normalization, and removing poor quality samples
and outliers with optional ﬁltering of low expressed miRNAs. There is currently no consensus on the
preferred normalization method for miRNA sequencing [76e78] and no established method for
evaluating the goodness of normalization [79]. The most frequently used normalization methods for
miRNA sequencing are the relative frequency and trimmed mean of M-values methods [80]. Filtering
of low expressed miRNAs in sequencing data can also be performed at this stage of the analysis. Many
normalization techniques are available for miRNA qRT-PCR and microarray analyses [79,81,82].
Normalization features are available on the free-access software (NSolver) that accompanies the
Nanostring nCounter System. Following preprocessing and cleaning, data can be analyzed as
required. The choice of an appropriate statistical method depends on the research in question, data
type and whether the data pass statistical test assumptions. ManneWhitney is a nonparametric test
commonly used for univariate analysis to differentiate clinical groups for a given miRNA.
KaplaneMeier curves are often used for survival and recurrence analysis. For multivariate analysis,
there is a wide range of various machine-learning and classiﬁcation techniques. However, according
to the “No free lunch theorem”, no machine-learning or classiﬁcation algorithm outperforms others
for any given data set [83] therefore, different methods may need to be tried to determine the best
method for a given data set.
Summary
miRNA-guided diagnostics is an increasingly powerful molecular approach for deriving clinically
signiﬁcant information from patient samples. To date, we know that miRNAs are excellent bio-
markers due to their abundance, cell-type speciﬁcity, and stability in most solid and liquid clinical
specimens. We also know that these small RNA molecules can be used to diagnose, manage, and
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odological issues confound or hinder translation into routine clinical practice. These issues are
currently being addressed by the miRNA community: miRNA database curation efforts are ongoing;
RNA extraction methods have been optimized for use on liquid samples so that miRNAs can be used
as minimally invasive biomarkers; detection assays are constantly updated to enable comprehensive
and accurate miRNA quantitation; online bioinformatics resources are being built for clinical pur-
poses; and the most appropriate statistical analyses are being identiﬁed for clinical testing. Additional
research is required to (i) fully understand miRNA expression in the human body, (ii) elucidate pre-
analytical variables that impact miRNA detection, (iii) develop novel or improve existing miRNA
detection methods, (iv) compare the performance of different miRNA detection platforms, and (v)
assess the feasibility of implementing miRNA testing in clinical practice. Through awareness of
existing issues and further research, we expect miRNA-guided diagnostics to provide much-needed
tissue and circulating biomarkers for the clinical management of endocrine cancers and metabolic
disorders.Practice points
(i) Be aware of scientific and methodological issues that can affect miRNA clinical testing.
(ii) Record pre-analytical variables for all clinical samples.
(iii) Assess RNA quality. Low RNA Integrity Numbers should not discourage miRNA clinical
testing.
(iv) Match miRNA detection method to diagnostic need. Establish criteria for accepting or
rejecting miRNA clinical test results.
(v) Use miRNA online resources to evaluate miRNA diagnostic tests and results.
(vi) For optimal miRNA-guided diagnostics, assemble a working group involving clinicians,
laboratory scientists, and statisticians.
Research agenda
To advance miRNA-guided diagnostics, the following research activities are recommended:
(i) Defining miRNA sequences thorough iterative miRNA database curation.
(ii) Establishing a comprehensive human miRNA expression atlas through profiling of
common and rare cell lines and dissociated tissues.
(iii) Evaluating the impact of pre-analytical variables on miRNA detection.
(iv) Designing novel and improving existing miRNA detection technologies.
(v) Performing cross-platform comparisons of miRNA detection methodologies.
(vi) Building user-friendly online resources for analyzing and comparing miRNA expression
data.
(vii) Elucidating the best statistical approaches for analyzing miRNA clinical data.
(viii) Performing feasibility studies for implementing and automating miRNA testing in routine
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